

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1. (Currently amended) A solution comprising about 0.01 to 0.05 mg mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline comprised within an indwelling catheter in which the flow of the fluids is obstructed by fibrin-bound blood clots, for at least about 5 days.

2. (Original) The solution of claim 1 wherein tenecteplase is in a concentration of about 0.01 to 0.04 mg/mL.

3. (Original) The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.03 mg/mL.

4. (Original) The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.02 mg/mL.

5. (Original) The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.15 mg/mL.

6. (Original) The solution of claim 1 wherein the tenecteplase is in sterile water for injection.

7. (Currently amended) An indwelling catheter containing a solution comprising about 0.01 to 0.05 mg mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline for a time sufficient to remove fibrin-bound blood clots obstructing the flow of fluids with no occlusions wherein the solution of claim 1 dwells within the catheter.

8. (New) The indwelling catheter of claim 7 wherein said solution is contained within the catheter for at least about 5 days.

9. (New) The indwelling catheter of claim 7 wherein said solution is contained within the catheter for at least about 6 to 15 days.